Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response maps each stated claim component (rodent thyroid C-cell tumors, unknown human relevance, contraindication for personal/family history of MTC or MEN 2, and patient counseling on symptoms) directly to the provided label excerpts with no contradictions identified.
Category Scores
Accurate Statements
Semaglutide causes thyroid C-cell tumors in rodents.
SECTION 5.1; SECTION 13.1 (statistically significant increase in thyroid C-cell adenomas and increased C-cell carcinomas in rodents)
The human relevance of the rodent thyroid C-cell tumor findings is unknown.
SECTION 5.1 ("It is unknown whether OZEMPIC causes thyroid C-cell tumors..." )
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
SECTION 4; SECTION 5.1
Patient counseling on symptoms of thyroid tumors is included (e.g., lump in the neck, hoarseness, dysphagia, dyspnea).
SECTION 5.1; SECTION 17
Unsupported Statements
Contradictions
Important Omissions
The AI response discusses thyroid C-cell tumors/mTC risk but does not explicitly address the label’s statements that routine monitoring (serum calcitonin or thyroid ultrasound) is of uncertain value for early detection and may increase unnecessary procedures.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response accurately covers key boxed-warning/contraindication and counseling elements for thyroid C-cell tumor risk. A potentially material omission is the label’s specific position on the uncertain value of routine calcitonin/ultrasound monitoring, but the assessed content remains within the provided excerpted focus.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Does not mention the label’s caution that routine serum calcitonin/thyroid ultrasound monitoring is of uncertain value and may lead to unnecessary procedures.
Suggested Improvement
Add a component explicitly stating that routine monitoring is of uncertain value per SECTION 5.1, and that elevated calcitonin requires further evaluation.